FREMONT, Calif. — Neuralink has begun its first human clinical trials of Blindsight, a brain-computer interface designed to restore vision for people who have lost the use of both eyes and optic nerves — marking a watershed moment in the company's mission to merge human biology with advanced technology.
Phase 1 of the trial enrolls 100 participants across the United States and Canada, all of whom have experienced complete blindness. Early results from initial test subjects are already generating cautious optimism: patients who have been blind for decades have begun reporting "phosphene flashes" — bursts of light and basic geometric outlines of their surrounding environment — as the device learns to translate camera input into neural signals.
How Blindsight Works
The Blindsight implant uses a high-density electrode array placed directly on the brain's visual cortex — the region responsible for processing sight. A small external camera, worn like a pair of glasses, continuously captures the visual environment and encodes that data into electrical signals delivered to the cortex in real time.
Unlike approaches that attempt to repair the eye or optic nerve, Blindsight bypasses the damaged biological pathway entirely, streaming digital vision data directly into the brain. The technology works even for patients whose blindness results from conditions that have destroyed the eye, retina, or optic nerve completely.
Resolution and Roadmap
Current capabilities deliver low-resolution, monochrome visual impressions — enough to perceive light, movement, and basic shapes. Neuralink's development roadmap targets basic color-spectrum recognition by end of year, with higher resolution following in subsequent hardware generations.
The company has been working toward this milestone since receiving FDA Breakthrough Device Designation in September 2024, a regulatory classification reserved for technologies that treat or diagnose serious conditions where existing therapies are inadequate. That designation accelerated Neuralink's path to first-in-human testing and grants the company ongoing collaboration with the FDA throughout the trial process.
Part of a Broader Neuralink Mission
Blindsight represents the second major clinical program at Neuralink, running alongside the company's PRIME study, which has already demonstrated that patients with paralysis can control computers, type text, and operate digital devices using only their thoughts via Neuralink's N1 implant.
Elon Musk has outlined plans to scale brain implants significantly in 2026, with an almost entirely automated surgical procedure reducing the time and cost of each implantation. The robotic surgical system — which Neuralink revealed can access virtually any region of the cortex with precision — is central to the company's ability to serve large patient populations at the scale required for clinical deployment.
What Comes Next
If Phase 1 results confirm the safety profile established in non-human primate trials, Neuralink intends to expand enrollment and begin refining stimulation algorithms to improve visual resolution further. The company has signaled that commercial availability — pending FDA approval — could follow within a few years of successful trial completion.
For the millions of people worldwide living with blindness from conditions like retinitis pigmentosa, glaucoma, or traumatic injury, Blindsight represents a genuinely new pathway to experiencing the visual world — one that is arriving faster than almost anyone anticipated just a few years ago.
